Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Promising New Approach to Drug-Resistant Infections

Published: Wednesday, October 16, 2013
Last Updated: Wednesday, October 16, 2013
Bookmark and Share
A new type of antibiotic called a PPMO, which works by blocking genes essential for bacterial reproduction, successfully killed a multidrug-resistant germ common to health care settings.

Researchers from UT Southwestern Medical Center believe the technology and new approach offer potential promise against the growing problem of antibiotic resistance.

The pathogen (germ) – called Acinetobacter – can cause infections from pneumonia to serious blood or wound infections, posing greater risk to people with weakened immune systems, chronic lung disease, or diabetes, according to the Centers for Disease Control and Prevention (CDC). Acinetobacter infection mainly affects hospitalized patients or those in long-term care facilities, such as those on ventilators or with urinary catheters or patients treated for open wounds. The CDC considers Acinetobacter, which is resistant to many antibiotics, one of the top bacterial infection threats in the U.S.

In the study in today’s Journal of Infectious Diseases, PPMOs designed to combat two strains of Acinetobacter reduced the number of infectious bacteria in mice by more than 90 percent. Survival of infected mice also improved with the treatment. One of the targeted strains was A. baumannii, a dangerous type that accounts for about 80 percent of reported Acinetobacter infections, according to the CDC.

“We set out to target specific genes in Acinetobacter in an effort to inhibit the bacterium’s growth,” said Dr. David Greenberg, assistant professor of internal medicine and microbiology and senior author of the study. “With infections from drug-resistant pathogens rising rapidly, there is an urgent need to come up with new approaches such as the use of PPMOs to spur antibiotic development.”

The technology that created the synthetic PPMO could be used to develop similar antibiotics targeting other bacteria and viruses, he added.

“We believe there is a lot of promise in developing new antibiotics that target specific pathogens as opposed to so-called broad-spectrum antibiotics that target whole classes of bacteria,” said Dr. Greenberg.

Whereas broad-spectrum antibiotics can kill off multiple pathogens, PPMOs are pathogen-specific and work by silencing essential genes that help that particular strain of bacteria or virus grow. A PPMO, or peptide-conjugated phosphorodiamidate morpholino oligomer, mimics the structure of a nucleic acid and binds to mRNA, preventing the formation of proteins. PPMOs have not been tested in humans, although a compound of similar chemical structure is being tested as a therapy in Duchenne muscular dystrophy patients.

More research is needed before the PPMOs are ready for human testing, said Dr. Greenberg, who was assisted in the study by Kimberly Marshall-Batty, a senior research associate in internal medicine.

Future studies will involve development and testing of PPMOs targeting other specific bacteria and virus types. Researchers also may try to create a PPMO that silences genes involved in antibiotic resistance.

The study involved researchers from UT Southwestern, Oregon State University, and Sarepta Inc., a Massachusetts-based pharmaceutical company that supplied the PPMOs for testing. Support for the study was provided by the National Institutes of Health. Prior to this study, Dr. Greenberg had served as a consultant to Sarepta. The study’s lead author at Oregon State formerly worked at AVI BioPharma, now called Sarepta, and holds several PPMO patents. Neither holds any equity interest or options in Sarepta. 


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

HIV Protein Manipulates Hundreds of Human Genes
Findings search for new or improved treatments for patients with AIDS.
Thursday, January 28, 2016
Enzyme Involved in Cell Division Also Plays a Role in Inflammation
NEK7 enzyme’s switch-like activity in immunity lead to new treatments for a variety of medical conditions linked to inflammation.
Thursday, December 10, 2015
Research Finding Could Lead to Targeted Therapies for IBD
Findings published online in Cell Reports.
Tuesday, December 01, 2015
Researchers Identify an Enzyme as a Major Culprit of Autoimmune Diseases
Inhibition of cGAS may be an effective therapy for autoimmune diseases.
Wednesday, October 28, 2015
Boosting Gut Bacteria Defense System May Lead to Better Treatments
Life-threatening bloodstream infections reversed by enhancing a specific immune defense response.
Tuesday, June 09, 2015
Immunity Enzyme Defends Against Tuberculosis Infection
Study shows that cGAS enzyme is essential for defense against the tuberculosis bacteria.
Wednesday, June 03, 2015
Researchers Find New Mechanism That Controls Immune Responses
The findings appear online in the journal Science.
Friday, February 13, 2015
New And Beneficial Function Of Endogenous Retroviruses In Immune Response Identified
ERV play a critical role in the body’s immune defense against common bacterial and viral pathogens.
Friday, December 19, 2014
Scientists Identify New and Beneficial Function of Endogenous Retroviruses
Researchers found that ERV play a critical role in the body’s immune defense against common bacterial and viral pathogens.
Friday, December 19, 2014
UT Southwestern Researcher Selected for ASBMB Merck Award
Award recognizes Dr. Zhijian Chen’s outstanding contributions to research in biochemistry and molecular biology.
Friday, July 18, 2014
Cellular Force That Drives Allergy and Asthma Can be Blocked by Interferon
Type I interferons block the development of allergy- and asthma-driving Th2 cells.
Friday, June 20, 2014
Study Identifies Potential New Strategy to Improve Odds of Corneal Transplant Acceptance
Study findings were reported in the December issue of the American Journal of Transplantation.
Tuesday, December 31, 2013
Identifying How Body Clock Affects Inflammation
UT Southwestern Medical Center researchers report that disrupting the light-dark cycle of mice increased their susceptibility to inflammatory disease.
Friday, November 08, 2013
Researchers Identify New Source of Powerful Immunity Protein
New cellular source for IFN-? that keeps viruses from replicating and stimulates the immune system.
Thursday, July 11, 2013
Dr. Bruce Beutler Elected to American Academy of Arts and Sciences
AAAS has elected Nobel Laureate Dr. Beutler of UT Southwestern Medical Center to membership.
Friday, April 26, 2013
Scientific News
Unique Mechanism for a High-Risk Leukemia
Researchers uncovered the aberrant mechanism underlying a notoriously treatment-resistant acute lymphoblastic leukemia subtype; findings offer lessons for understanding all cancers.
Food Triggers Creation of Regulatory T Cells
IBS researchers document how normal diet establishes immune tolerance conditions in the small intestine.
Therapeutic Approach Gives Hope for Multiple Myeloma
A new therapeutic approach tested by a team from Maisonneuve-Rosemont Hospital (CIUSSS-EST, Montreal) and the University of Montreal gives promising results for the treatment of multiple myeloma, a cancer of the bone marrow currently considered incurable with conventional chemotherapy and for which the average life expectancy is about 6 or 7 years.
Cellular 'Relief Valve'
A team led by scientists at The Scripps Research Institute (TSRI) has solved a long-standing mystery in cell biology by showing essentially how a key “relief-valve” in cells does its job.
Switch Lets Salmonella Fight, Evade Immune System
Researchers at the University of Illinois at Chicago have discovered a molecular regulator that allows salmonella bacteria to switch from actively causing disease to lurking in a chronic but asymptomatic state called a biofilm.
Tricked-Out Immune Cells Could Attack Cancer
New cell-engineering technique may lead to precision immunotherapies.
Neural Networks Adapt to the Presence of a Toxic HIV Protein
HIV-associated neurocognitive disorders (HAND) afflict approximately half of HIV infected patients.
HIV Protein Manipulates Hundreds of Human Genes
Findings search for new or improved treatments for patients with AIDS.
Breaking the Brain’s Garbage Disposal
The children’s ataxia gene problem turned out to be not such a big deal genetically — it was such a slight mutation that it barely changed the way the cells made the protein.
Flesh-Eating Bacteria Work Together
Scientists recently discovered different strains of deadly flesh-eating bacteria working together to spread infection and they now have a better understanding of the role of the toxins they produce. The discovery could change how the illness and other diseases are treated.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!